Thomas E. Hutson

50.9k total citations · 9 hit papers
292 papers, 24.8k citations indexed

About

Thomas E. Hutson is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Molecular Biology. According to data from OpenAlex, Thomas E. Hutson has authored 292 papers receiving a total of 24.8k indexed citations (citations by other indexed papers that have themselves been cited), including 258 papers in Pulmonary and Respiratory Medicine, 135 papers in Cancer Research and 129 papers in Molecular Biology. Recurrent topics in Thomas E. Hutson's work include Renal cell carcinoma treatment (223 papers), Cancer Genomics and Diagnostics (127 papers) and Renal and related cancers (113 papers). Thomas E. Hutson is often cited by papers focused on Renal cell carcinoma treatment (223 papers), Cancer Genomics and Diagnostics (127 papers) and Renal and related cancers (113 papers). Thomas E. Hutson collaborates with scholars based in United States, France and Italy. Thomas E. Hutson's co-authors include Robert J. Motzer, Stéphane Oudard, Robert A. Figlin, Ronald M. Bukowski, Sylvie Négrier, Cezary Szczylik, Bernard Escudier, M. Dror Michaelson, Piotr Tomczak and Sindy T. Kim and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Thomas E. Hutson

285 papers receiving 24.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

2007 4.5k citations Robert J. Motzer, Thomas E. Hutson et al. profile →
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma

2007 3.8k citations Bernard Escudier, Tim Eisen et al. profile →
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

2008 2.3k citations Robert J. Motzer, Bernard Escudier et al. The Lancet profile →
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

2009 1.7k citations Robert J. Motzer, Thomas E. Hutson et al. Journal of Clinical Oncology profile →
Phase 3 trial of everolimus for metastatic renal cell carcinoma

2010 903 citations Robert J. Motzer, Bernard Escudier et al. Cancer profile →
Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

2009 864 citations Bernard Escudier, Tim Eisen et al. Journal of Clinical Oncology profile →
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial

2015 688 citations Robert J. Motzer, Thomas E. Hutson et al. profile →
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

2013 542 citations Robert J. Motzer, Bernard Escudier et al. profile →
Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy

2011 457 citations Thomas E. Hutson et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Thomas E. Hutson

Since Specialization

Citations

This map shows the geographic impact of Thomas E. Hutson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas E. Hutson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas E. Hutson more than expected).

Fields of papers citing papers by Thomas E. Hutson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas E. Hutson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas E. Hutson. The network helps show where Thomas E. Hutson may publish in the future.

Co-authorship network of co-authors of Thomas E. Hutson

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas E. Hutson. A scholar is included among the top collaborators of Thomas E. Hutson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas E. Hutson. Thomas E. Hutson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Optimizing Pharmacotherapy During Implementation of Enhanced Recovery After Surgery (ERAS) in Ambulatory Urologic Oncology Surgery: Narrative Review 2025 ·Cancers ·(unknown), Thomas E. Hutson, Eric A. Singer, Saum Ghodoussipour	0
2	Development of a FKSI-23: A new bespoke health-related quality of life (HRQOL) questionnaire for the advanced and adjuvant setting in renal cell carcinoma (RCC). 2025 ·Journal of Clinical Oncology ·Cristiane Decat Bergerot, Paulo Gustavo Bergerot, (unknown), (unknown), (unknown), (unknown), Thomas E. Hutson, Axel Bex, Sarah P. Psutka, Brian I. Rini, Elizabeth R. Plimack, Viraj A. Master, Viktor Grünwald, Laurence Albigès, Toni K. Choueiri, Sumanta K. Pal, David Cella, Thomas Powles	0
3	5 A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC-7366 in Combination with Belzutifan (WELIREGTM) in Patients with Advanced or Metastatic Renal Cell Carcinoma, NCT06234605 2024 ·The Oncologist ·Rana R. McKay, (unknown), Pedro C. Barata, Moshe Chaim Ornstein, Neil J. Shah, Hans J. Hammers, Thomas E. Hutson, Michael Chisamore, (unknown), (unknown), Eric S. Lightcap, (unknown), Ben J. Harrison, (unknown), Nandita Bose, (unknown), Robert J. Motzer	1
4	A phase 1b study of NC410 in combination with pembrolizumab in immune checkpoint inhibitor (ICI) naïve, and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer. 2024 ·Journal of Clinical Oncology ·Eric S. Christenson, Daruka Mahadevan, Syed Mohammad Ali Kazmi, Sudhir Manda, Davendra Sohal, Thomas E. Hutson, Siqing Fu, (unknown), (unknown), Emilia Alina Barbu, Dallas B. Flies, Solomon Langermann, Michael Chisamore, Martin Gutierrez, Marc Matrana, (unknown), Raymond Wadlow, (unknown), (unknown), Dung T. Le	2
5	Biomarker analyses in patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial. 2024 ·Journal of Clinical Oncology ·Robert J. Motzer, Camillo Porta, Masatoshi Eto, Thomas E. Hutson, Sun Young Rha, Jaime R. Merchan, Eric Winquist, Howard Gurney, Viktor Grünwald, Saby George, (unknown), Joseph E. Burgents, Răzvan Cristescu, Y. Narita, Cixin He, Zi-Ming Zhao, Chinyere E. Okpara, Yukinori Minoshima, Toni K. Choueiri	7
6	Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial 2024 ·The Oncologist ·Kathryn E. Beckermann, Aviva G. Asnis-Alibozek, Michael B. Atkins, Bernard Escudier, Thomas E. Hutson, Vijay Kasturi, David F. McDermott, Sumanta K. Pal, Camillo Porta, Brian I. Rini, Elena Verzoni	8
7	Plain Language Summary Looking at How Long Side Effects Last After Treatment with Axitinib is Stopped in People with Advanced Renal Cell Carcinoma 2023 ·Future Oncology ·Brian I. Rini, Michael B. Atkins, Toni K. Choueiri, Rosemary E. Teresi, Brad Rosbrook, (unknown), Thomas E. Hutson	1
8	Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney Cancer 2022 ·Clinical Genitourinary Cancer ·Zeynep Büşra Zengin, Sumanta K. Pal, David F. McDermott, Bernard Escudier, Thomas E. Hutson, Camillo Porta, Elena Verzoni, Michael B. Atkins, Vijay Kasturi, Brian I. Rini	3
9	Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated with Axitinib: Subgroup Analysis from TIVO-3 2022 ·The Oncologist ·Luís Meza, David F. McDermott, Bernard Escudier, Thomas E. Hutson, Camillo Porta, Elena Verzoni, Michael B. Atkins, Vijay Kasturi, Sumanta K. Pal, Brian I. Rini	2
10	Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial 2022 ·BMJ Open ·Daniel J. George, David R. Spigel, Lucio Gordan, Samith T. Kochuparambil, Ana M. Molina, (unknown), Arash Rezazadeh Kalebasty, (unknown), Nishan Tchekmedyian, Scott S. Tykodi, Joshua Zhang, Margarita Askelson, Jennifer L. Johansen, Thomas E. Hutson	4
11	Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell Carcinoma 2021 ·Clinical Genitourinary Cancer ·Brian I. Rini, Michael B. Atkins, Toni K. Choueiri, Despina Thomaidou, Brad Rosbrook, (unknown), Thomas E. Hutson	13
12	Q-TWiST Analysis of Tivozanib Versus Sorafenib in Patients With Advanced Renal Cell Carcinoma in the TIVO-3 Study 2021 ·Clinical Genitourinary Cancer ·Michael Szarek, Michael N. Needle, Brian I. Rini, Sumanta K. Pal, David F. McDermott, Michael B. Atkins, Thomas E. Hutson, Bernard Escudier	7
13	Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma 2014 ·Cancer Chemotherapy and Pharmacology ·Robert J. Motzer, Thomas E. Hutson, Gary R. Hudes, Robert A. Figlin, Jean-François Martini, Patricia A. English, Xin Huang, Olga Valota, James A. Williams	56
14	The Role of Aberrant VHL/HIF Pathway Elements in Predicting Clinical Outcome to Pazopanib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma 2013 ·Clinical Cancer Research ·Toni K. Choueiri, André P. Fay, Robert Gagnon, Ying Lin, Brittany Bahamón, Victoria E. Brown, Jonathan E. Rosenberg, Thomas E. Hutson, Katherine L. Baker-Neblett, Christopher L. Carpenter, Yuan Liu, Lini Pandite, Sabina Signoretti	73
15	Sunitinib rechallenge in metastatic renal cell carcinoma patients 2010 ·Cancer ·Ivan Zama, Thomas E. Hutson, Paul Elson, James M. Cleary, Toni K. Choueiri, Daniel Y.C. Heng, Nikhil H. Ramaiya, M. Dror Michaelson, Jorge A. García, Jennifer J. Knox, Bernard Escudier, Brian I. Rini	108
16	Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma breakdown → 2009 ·Journal of Clinical Oncology ·Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak, M. Dror Michaelson, Ronald M. Bukowski, Stéphane Oudard, Sylvie Négrier, Cezary Szczylik, Роберто Пили, Georg A. Bjarnason, Xavier García del Muro, Jeffrey A. Sosman, E Solska, George Wilding, John A. Thompson, Sindy T. Kim, Isan Chen, Xin Huang, Robert A. Figlin	1711
17	Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial breakdown → 2009 ·Journal of Clinical Oncology ·Bernard Escudier, Tim Eisen, Walter M. Stadler, Cezary Szczylik, Stéphane Oudard, Michael Staehler, Sylvie Négrier, Christine Chevreau, Apurva A. Desai, Frédéric Rolland, Tomasz Demkow, Thomas E. Hutson, Martin Gore, Sibyl Anderson, (unknown), Minghua Shan, Carol Peña, Chetan Lathia, Ronald M. Bukowski	864
18	Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma 2009 ·Journal of Clinical Oncology ·Bernard Escudier, Cezary Szczylik, Thomas E. Hutson, Tomasz Demkow, Michael Staehler, Frédéric Rolland, Sylvie Négrier, Nicole Laferriere, Urban Scheuring, David Cella, Sonalee Shah, Ronald M. Bukowski	378
19	Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma 2008 ·Journal of Clinical Oncology ·Brian I. Rini, M. Dror Michaelson, Jonathan E. Rosenberg, Ronald M. Bukowski, Jeffrey A. Sosman, Walter M. Stadler, Thomas E. Hutson, Kim Margolin, Charles S. Harmon, Samuel E. DePrimo, Sindy T. Kim, Isan Chen, Daniel J. George	321
20	Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial breakdown → 2008 ·The Lancet ·Robert J. Motzer, Bernard Escudier, Stéphane Oudard, Thomas E. Hutson, Camillo Porta, Sergio Bracarda, Viktor Grünwald, John A. Thompson, Robert A. Figlin, Norbert Hollaender, Gladys Urbanowitz, William J. Berg, Andrea Kay, David Lebwohl, Alain Ravaud	2339

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact